52 North Health, a UK and US-based med-tech start-up, has raised £1 million in its first round of funding from leading UK and European specialist investors.
The round was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, with participation from Crista Galli Ventures, King’s Health Partners MedTech Innovations, Meltwind, Milltrust Ventures and a number of angels.
52 North is developing the NeutroCheck: a fully-integrated clinical, AI and medical device-based system for people living with cancer.
The investment will be used to take the NeutroCheck device through clinical trials in the UK, as well as to deliver on strategic partnerships with key partners including the UK Sepsis Trust and Macmillan Cancer Support, in order to define a new clinical pathway for treating suspected neutropenic sepsis, and to ensure people living with disease continue to be at the heart of the product life-cycle.
